CoChat

DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome

Todoerti, Katia, Ronchetti, Domenica, Favasuli, Vanessa, Maura, Francesco, Morabito, Fortunato, Bolli, Niccolò, Taiana, Elisa, Neri, Antonino · 2021 · Haematologica
Cited by 34

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

DIS3 gene mutations occur in roughly 10% of patients with multiple myeloma (MM); furthermore, DIS3 expression can be affected by monosomy 13 and del(13q), which occur in approximately 40% of MM cases. Despite several reports on the prevalence of DIS3 mutations, their contribution to the pathobiology of MM remains largely unknown. We took advantage of the large public CoMMpass dataset to investigate the spectrum of DIS3 mutations in MM and its impact on the transcriptome and clinical outcome. We found that the clinical relevance of DIS3 mutations strictly depended on the co-occurrence of del(13q). In particular, bi-allelic DIS3 lesions significantly affected progression-free survival, independently of other predictors of poor clinical outcome, while mono-allelic events mostly affected overall survival. As expected, DIS3 mutations affect the MM transcriptome involving cellular processes and signaling pathways associated with RNA metabolism, and the deregulation of a large number of long non-coding RNA, among which we identified five distinct transcripts as independent predictors of poorer overall survival and nine of worse progression-free survival, with two (AC015982.2 and AL445228.3) predicting both unfavorable outcomes. These findings strongly prompt further studies investigating the relevance of these long non-coding RNA in MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2021.278342

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 34

  1. Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013; 19(13):3337-3344. · DOI · Paper page
  2. Barbieri M, Manzoni M, Fabris S. Compendium of FAM46C gene mutations in plasma cell dyscrasias. Br J Haematol. 2016; 174(4):642-645. · DOI
  3. Chapman MA, Lawrence MS, Keats JJ. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-472. · DOI · Paper page
  4. Lionetti M, Barbieri M, Manzoni M. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. Oncotarget. 2016; 7(16):21353-21361. · DOI
  5. Lionetti M, Barbieri M, Todoerti K. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget. 2015; 6(28):26129-26141. · DOI · Paper page
  6. Bolli N, Biancon G, Moarii M. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018; 32(12):2604-2616. · DOI · Paper page
  7. D'Agostino M, Zaccaria GM, Ziccheddu B. Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing. Clin Cancer Res. 2020; 26(18):4832-4841. · DOI
  8. Walker BA, Mavrommatis K, Wardell CP. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019; 33(1):159-170. · DOI · Paper page
  9. Tomecki R, Drazkowska K, Kucinski I. Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target. Nucleic Acids Res. 2014; 42(2):1270-1290. · DOI · Paper page
  10. Schneider C, Leung E, Brown J, Tollervey D. The N-terminal PIN domain of the exosome subunit Rrp44 harbors endonuclease activity and tethers Rrp44 to the yeast core exosome. Nucleic Acids Res. 2009; 37(4):1127-1140. · DOI · Paper page
  11. Lorentzen E, Basquin J, Tomecki R, Dziembowski A, Conti E. Structure of the active subunit of the yeast exosome core, Rrp44: diverse modes of substrate recruitment in the RNase II nuclease family. Mol Cell. 2008; 29(6):717-728. · DOI · Paper page
  12. Tomecki R, Drazkowska K, Dziembowski A. Mechanisms of RNA degradation by the eukaryotic exosome. Chembiochem. 2010; 11(7):938-945. · DOI · Paper page
  13. Boyle EM, Ashby C, Tytarenko RG. BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma. Clin Cancer Res. 2020; 26(10):2422-2432. · DOI · Paper page
  14. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017; 14(2):100-113. · DOI · Paper page
  15. Binder M, Rajkumar SV, Ketterling RP. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017; 7(9):e600. · DOI
  16. Chiecchio L, Dagrada GP, Ibrahim AH. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica. 2009; 94(12):1708-1713. · DOI
  17. Chesi M, Stein CK, Garbitt VM. Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov. 2020; 1(1):68-81. · DOI · Paper page
  18. de Groen FL, Krijgsman O, Tijssen M. Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression. Genes Chromosomes Cancer. 2014; 53(4):339-348. · DOI · Paper page
  19. Weissbach S, Langer C, Puppe B. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol. 2015; 169(1):57-70. · DOI · Paper page
  20. Segalla S, Pivetti S, Todoerti K. The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA. Nucleic Acids Res. 2015; 43(10):5182-5193. · DOI · Paper page
  21. Schadt EE, Li C, Ellis B, Wong WH. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl. 2001; Suppl 37:120-125. · DOI · Paper page
  22. Chen L, Li Q, She T. IRE1alpha-XBP1 signaling pathway, a potential therapeutic target in multiple myeloma. Leuk Res. 2016; 49:7-12. · DOI
  23. Sigova AA, Mullen AC, Molinie B. Divergent transcription of long noncoding RNA/mRNA gene pairs in embryonic stem cells. Proc Natl Acad Sci U S A. 2013; 110(8):2876-2881. · DOI · Paper page
  24. Tan JY, Smith AAT, Ferreira da Silva M. Cis-acting complex-trait-associated lincRNA expression correlates with modulation of chromosomal architecture. Cell Rep. 2017; 18(9):2280-2288. · DOI
  25. Trinklein ND, Aldred SF, Hartman SJ, Schroeder DI, Otillar RP, Myers RM. An abundance of bidirectional promoters in the human genome. Genome Res. 2004; 14(1):62-66. · DOI · Paper page
  26. Pefanis E, Basu U. RNA exosome regulates AID DNA mutator activity in the B cell genome. Adv Immunol. 2015; 127:257-308. · DOI
  27. Chlebowski A, Lubas M, Jensen TH, Dziembowski A. RNA decay machines: the exosome. Biochim Biophys Acta. 2013; 1829(6-7):552-560. · DOI · Paper page
  28. Higgins LG, Hayes JD. Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents. Drug Metab Rev. 2011; 43(2):92-137. · DOI · Paper page
  29. Xu B, Qin T, Yu J, Giordano TJ, Sartor MA, Koenig RJ. Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma. J Biol Chem. 2020; 295(26):8834-8845. · DOI
  30. Chapman J, Ng YS, Nicholls TJ. The maintenance of mitochondrial DNA integrity and dynamics by mitochondrial membranes. Life. 2020; 10(9):164. · DOI · Paper page
  31. Davidson L, Francis L, Cordiner RA. Rapid depletion of DIS3, EXOSC10, or XRN2 reveals the immediate impact of exoribonucleolysis on nuclear RNA metabolism and transcriptional control. Cell Rep. 2019; 26(10):2779-2791.e5. · DOI · Paper page
  32. Kiss DL, Andrulis ED. Genome-wide analysis reveals distinct substrate specificities of Rrp6, Dis3, and core exosome subunits. RNA. 2010; 16(4):781-791. · DOI · Paper page
  33. Milbury KL, Paul B, Lari A. Exonuclease domain mutants of yeast DIS3 display genome instability. Nucleus. 2019; 10(1):21-32. · DOI · Paper page
  34. Rigby RE, Rehwinkel J. RNA degradation in antiviral immunity and autoimmunity. Trends Immunol. 2015; 36(3):179-188. · DOI

Cited by

See all 34

Metadata

Authors
Todoerti, K., Ronchetti, D., Favasuli, V., Maura, F., Morabito, F., Bolli, N., Taiana, E., & Neri, A.
Venue
Haematologica
Published
2021-05-06
Volume
107
Issue
4
Pages
921-932
ISSN
  • 1592-8721
  • 0390-6078
Cited by
34
References
5

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. https://app.cochat.ai/papers/10.3324/haematol.2021.278342
The paper
Todoerti, K., Ronchetti, D., Favasuli, V., Maura, F., Morabito, F., Bolli, N., Taiana, E., & Neri, A. (2021). DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. Haematologica. https://doi.org/10.3324/haematol.2021.278342

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.